Nuvisan announces the first winner of the 1st NUVISAN Drug Discovery Innovation Challenge: ARGO Therapeutics

Nuvisan Berlin, a fully integrated contract research service provider for drug discovery and development, announced on March 30th the winners of the 1st NUVISAN Drug Discovery Innovation Challenge at the 2nd Nuvisan and VC Forum. With this program Nuvisan aims at supporting scientific innovation, especially for start-ups and biotech companies that are developing therapies in specific fields. In this first Challenge, Nuvisan focused on inflammatory diseases.

The top winner, ARGO Tx (Switzerland), is developing a novel therapeutic for Parkinson’s disease (PD) targeting a multi-acting nuclear receptor Nurr1 (NR4A2), a long-thought therapeutic target for brain diseases. The team is developing a portfolio of clinical standards therapeutics and the most promising therapeutics will enter the clinic in 2023. Thanasis Spathis, CEO and Co-founder of ARGO Tx had the opportunity of presenting their idea in front of a selected group of international Venture Capitals in the Showcase section during 2nd Nuvisan and VC Partners Forum. ‘’We are delighted that ARGO has won the 1st NUVISAN challenge and that we pitched one of our main projects in front of a targeted international audience of VCs. We strongly believe that events such as Nuvisan’ s initiative to establish the Drug Discovery Innovation Challenge, validate further our selected project and significantly increase the visibility of ARGO, towards supporting our fundraising strategy”, according to Thanasis Spathis, ARGO Therapeutics, CEO. 

"The desire to help the start-up community get through the first phase of success is critically important for Nuvisan; therefore, we are happy to set up this initiative and we congratulate ARGO on being the first winner” quoted Arnoud Huisman, former Managing Director of Nuvisan Berlin and Chief Strategy Officer of the Nuvisan group.